1. Home
  2. NAMS vs TWST Comparison

NAMS vs TWST Comparison

Compare NAMS & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • TWST
  • Stock Information
  • Founded
  • NAMS 2019
  • TWST 2013
  • Country
  • NAMS Netherlands
  • TWST United States
  • Employees
  • NAMS N/A
  • TWST N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • TWST Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NAMS Health Care
  • TWST Health Care
  • Exchange
  • NAMS Nasdaq
  • TWST Nasdaq
  • Market Cap
  • NAMS 2.7B
  • TWST 2.3B
  • IPO Year
  • NAMS N/A
  • TWST 2018
  • Fundamental
  • Price
  • NAMS $26.73
  • TWST $27.95
  • Analyst Decision
  • NAMS Strong Buy
  • TWST Buy
  • Analyst Count
  • NAMS 10
  • TWST 9
  • Target Price
  • NAMS $41.40
  • TWST $50.67
  • AVG Volume (30 Days)
  • NAMS 984.0K
  • TWST 1.4M
  • Earning Date
  • NAMS 11-05-2025
  • TWST 11-17-2025
  • Dividend Yield
  • NAMS N/A
  • TWST N/A
  • EPS Growth
  • NAMS N/A
  • TWST N/A
  • EPS
  • NAMS N/A
  • TWST N/A
  • Revenue
  • NAMS $64,006,000.00
  • TWST $362,273,000.00
  • Revenue This Year
  • NAMS N/A
  • TWST $22.12
  • Revenue Next Year
  • NAMS $1.67
  • TWST $17.27
  • P/E Ratio
  • NAMS N/A
  • TWST N/A
  • Revenue Growth
  • NAMS 762.15
  • TWST 22.72
  • 52 Week Low
  • NAMS $14.06
  • TWST $24.07
  • 52 Week High
  • NAMS $27.35
  • TWST $55.33
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 59.23
  • TWST 53.39
  • Support Level
  • NAMS $23.05
  • TWST $24.07
  • Resistance Level
  • NAMS $27.35
  • TWST $25.96
  • Average True Range (ATR)
  • NAMS 1.52
  • TWST 1.35
  • MACD
  • NAMS -0.11
  • TWST 0.44
  • Stochastic Oscillator
  • NAMS 85.58
  • TWST 88.38

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

Share on Social Networks: